Amoxapine as an antipsychotic: comparative study versus haloperidol

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Neuroscience

Background:

• Atypical antipsychotics' reduced extrapyramidal side effects (EPS) are linked to D2 receptor affinity and 5HT2 receptor interactions.
• Amoxapine, an antidepressant, exhibits similar receptor binding profiles to atypical antipsychotics and preclinical effects.

Purpose of the Study:

• To investigate the antipsychotic efficacy and side effect profile of amoxapine compared to haloperidol in schizophrenia patients.
• To evaluate amoxapine's potential as an atypical antipsychotic based on its receptor binding characteristics.

Main Methods:

• A 6-week, double-blind study involving 54 schizophrenia patients.
• Patients received either amoxapine (150 mg/d) or haloperidol (5 mg/d), with clinical assessments at regular intervals.

Main Results:

• Both amoxapine and haloperidol significantly improved positive and total symptom scores on the Positive and Negative Syndrome Scale (PANSS).
• Amoxapine showed additional benefits in negative symptoms and Clinical Global Impression, with no significant differences in overall efficacy between groups.
• No significant differences were observed in depression scores, side effect checklists, or prolactin levels between the two treatment groups.

Conclusions:

• Amoxapine exhibits antipsychotic effectiveness comparable to haloperidol in schizophrenia, aligning with its D2 and 5HT2 receptor affinity.
• Amoxapine did not demonstrate a superior side effect profile regarding extrapyramidal symptoms compared to haloperidol in this patient cohort.